Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with a Veterans Affairs Medical Center.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 30442822.
- Also identified by DOI 10.3899/jrheum.180393.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate the efficacy and safety of anakinra in inpatient management of acute gout and pseudogout. Hospitalized patients with acute gout (n = 77) or pseudogout (n = 11) or both (n = 3) were analyzed for response to anakinra and adverse effects. Half of all patients had comorbidities limiting the treatment choice. Anakinra was well tolerated, and 92% of gout flares and 79% of pseudogout flares responded to treatment. Anakinra is an effective and safe treatment for acute gout and pseudogout in hospitalized patients, particularly in those with comorbidities.
Medical subject headings
- Antirheumatic Agents
- Arthritis, Gouty
- Chondrocalcinosis
- Hospitals, University
- Interleukin 1 Receptor Antagonist Protein